You are here
Telix and Nihon Medi-Physics to Collaborate on Renal Cancer Imaging for the Japanese Market
MELBOURNE, Australia and KYOTO, Japan and TOKYO, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), and Nihon Medi-Physics Co., Ltd. (“NMP”), a leading manufacturer and supplier of radiopharmaceuticals and related products in Japan, have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.
The agreement between Telix and NMP is focused on Telix’s TLX250 imaging program for renal cancer with Positron Emission Tomography (PET). Under the terms of the agreement, Telix and NMP will work together to establish a commercial partnership for TLX250 in Japan, with the objective of appointing NMP as an exclusive partner for the product in Japan. NMP will also support Telix in the near-term goal of including Japanese patients in Telix’s global Phase III development program for TLX250.
Telix Pharmaceuticals Japan President, Dr. Shintaro Nishimura, stated, “NMP is a leading company in the Japanese radiopharmaceutical landscape with a strong track record of stable supply of PET imaging agents. As we develop our Japanese regulatory strategy for TLX250, we are pleased to have the experience and guidance of NMP.”
NMP President, Mr. Hisashi Shimoda noted, “The technologies in which diagnostics and therapeutics are integrated will become increasingly important to the personalized medicine strategy for cancer treatment. TLX250 has the potential to become one of the best PET products in this field. Our goal is to identify and enrich our portfolio by new products and technologies that meet unmet medical need. It is our pleasure to collaborate with Telix to deliver new renal imaging capabilities to Japanese patients.”
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.
TLX250 (Girentuximab) is being developed by Telix Pharmaceuticals both as a diagnostic PET agent - 89Zr-Girentuximab (Phase III) and a therapeutic drug – 177Lu-Girentuximab (Phase II). TLX250 is an antibody-based platform that targets carbonic anhydrase IX (CAIX), a cell surface target that is over-expressed in several serious cancers, including renal, lung and esophageal cancer. High CAIX tumour expression is generally correlated with poor prognosis.
Telix has prioritized the development of TLX250 for metastatic renal cell cancer (RCC), particularly the clear cell variant (ccRCC), which almost ubiquitously over-expresses CAIX.
About Nihon Medi-Physics Co., Ltd.
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.
None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration or the Japanese PMDA.
CONTACT: Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: firstname.lastname@example.org Telix Investor Relations (US) Lisa Wilson In-Site Communications Tel: +1 212 452 2793 Email: email@example.com Telix Investor Relations (Australia) Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: firstname.lastname@example.org Nihon Medi-Physics Contacts (Japan) Hiroyuki Okudaira Research & Business Development Dept. Tel: +81 3 6680 8933 Email: email@example.com Corporate Communication Tel: +81 3 5634 7006